Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

AUTL Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Autolus Therapeutics plcNASDAQ: AUTL

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -$11.22M, compared with -$2.7M a year earlier. Trailing-twelve-month other income / expenses was -$23.51M.

Context

  • Other income / expenses amounted to 20.4% of revenue in FY2025, down 199.9 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$11.22M or moves back toward the trailing-twelve-month quarterly average of -$5.88M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.22M+41.0% QoQ
Last fiscal yearDec 2025
-$15.41M-169.1% YoY
LTMMar 2026
-$23.51M-111.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-315.8%——
1 year-169.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(15.41M) USD
Year-over-year change
-169.1%

Other Income / Expenses vs competitors

How AUTL compares with its peers on the latest reported figures

  • AUTL's LTM Mar 2026 other income / expenses of -$23.51M is the 9th highest of the 10 companies compared; the peer median is -$2.06M.
  • Its year-over-year change of -111.8% is the 6th highest of 10, against a peer median of -61.3%.
  • Other income / expenses amounts to 25.4% of revenue for AUTL, versus a peer median of 18.4%.
AUTL Competitors Peer median
Other Income / Expenses for AUTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$16.46M -3.2%——
FATEFate Therapeutics, Inc.LTM Mar 2026$9.52M -61.3%-24.7%150.7%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$9.09M -27.2%+21.7%—
LEGNLegend Biotech CorporationLTM Sep 2026-$1.9M +94.1%—0.1%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$2.06M -113.1%—18.4%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$3.13M -36.7%—13.5%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$5.37M -124.3%—11.9%
CLLSCellectis S.A.LTM Mar 2026-$23.45M -215.6%—34.4%
AUTLAutolus Therapeutics plcLTM Mar 2026-$23.51M -111.8%—25.4%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$54.54M -309.6%—175948.4%
Peer median (excluding AUTL) -$2.06M-61.3%-1.5%18.4%

Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.51M6.19M1.7M10.12M75.56M
Cost of Revenue000141.02M96.59M
Gross Profit1.51M6.19M1.7M(130.9M)(21.03M)
Gross Margin100.0%100.0%100.0%-1293.5%-27.8%
Research & Development110.84M117.35M130.48M158.14M128.59M
Selling, General & Admin31.87M31.9M46.75M0131.82M
Operating Expenses141.88M149.09M181.4M110.53M260.41M
Depreciation & Amortization8.46M7.42M6.57M7.72M9.84M
EBITDA(132.48M)(132.24M)(156.77M)(233.07M)(250.26M)
EBITDA Margin-8790.6%-2135.0%-9232.6%-2303.1%-331.2%
Operating Income(140.37M)(142.89M)(179.7M)(241.43M)(281.44M)
Operating Margin-9314.8%-2307.0%-10583.1%-2385.6%-372.4%
Interest Income262K1.71M13.51M32.36M19.02M
Interest Expense1.11M8.91M45.07M9.29M36.76M
Other Income / Expenses(1.66M)(5.67M)(28.7M)22.29M(15.41M)
Income Before Tax(142.04M)(148.57M)(208.4M)(219.13M)(296.85M)
Pre-Tax Margin-9425.2%-2398.6%-12273.4%-2165.4%-392.8%
Income Tax Expense58K272K(19K)1.53M(8.65M)
Net Income(142.1M)(148.84M)(208.38M)(220.66M)(288.2M)
Net Margin-9429.1%-2403.0%-12272.3%-2180.5%-381.4%
EPS (Basic)(1.97)(1.57)(1.20)(0.87)(1.08)
EPS (Diluted)(1.97)(1.57)(1.20)(0.87)(1.08)
Weighted Avg Shares72.08M94.99M173.94M255.16M266.14M
Weighted Avg Shares (Diluted)72.08M94.99M173.94M255.16M266.14M

Autolus Therapeutics plc

NASDAQ:AUTL

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.